pharmaphorum
FEBRUARY 18, 2021
Merck will pair Keytruda (pembrolizumab) with bempegaldesleukin (NKTR-214) – known as bempeg for short – in a phase 2/3 trial involving patients with squamous cell carcinoma of the head and neck (SCCHN) that if positive could support regulatory filings. That was signed for $1.8
Scienmag
NOVEMBER 18, 2021
Louis and Massachusetts General Hospital/Harvard Medical School in Boston have received a seven-year, $22 million grant from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) to help lead a multicenter clinical trial evaluating whether a novel immunosuppressant can […].
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
STAT News
AUGUST 17, 2022
National Institutes of Health failed to ensure that results of roughly half of clinical trials funded by the agency — both those conducted by its own scientists and outside researchers — were reported to a federal database during a recent two-year period, a new government review has found.
Rethinking Clinical Trials
JULY 31, 2023
The NIH this month published notice of a funding opportunity to support the next round of pragmatic clinical trials within the NIH-DoD-VA Pain Management Collaboratory (PMC). Read the full notice of funding opportunity (RFA-AT-24-004). The PMC was established in 2017 with an initial cohort of 11 pragmatic trials.
Pharma in Brief
JUNE 26, 2022
On June 22, 2022, the Canadian Institutes of Health Research ( CIHR ) announced the launch of the Clinical Trials Fund ( CTF ), which will inject funding into Canada’s clinical trials environment. The Clinical Trials Fund. Clinical Trials Training Platforms ( CTTP ). Clinical Trials Projects.
pharmaphorum
SEPTEMBER 16, 2020
Adding Eli Lilly’s rheumatoid arthritis drug Olumiant (baricitinib) and Gilead Sciences’ remdesivir reduces recovery time in COVID-19 patients compared to remdesivir alone, says a new trial. The post Trial backs Lilly’s Olumiant plus remdesivir as combo COVID-19 therapy appeared first on.
BioSpace
JUNE 10, 2024
While a prolonged, 15-day regimen of Paxlovid is safe, it appears to be ineffective at lowering the symptoms of long COVID, according to results of a Phase II trial funded by Pfizer and conducted by Stanford Medicine.
Expert insights. Personalized for you.
98 
Let's personalize your content